Product
Sapanisertib
Aliases
INK128, INK-128, MLN0128, MLN-0128 (1 other aliases)
Name
Sapanisertib
16 clinical trials
60 indications
Indication
Breast CancerIndication
CancerIndication
Breast NeoplasmsIndication
GlioblastomaIndication
Endometrial Clear Cell AdenocarcinomaIndication
Endometrial Serous AdenocarcinomaIndication
Clear Cell Ovarian CancerIndication
Endometrioid ovarian adenocarcinomaIndication
Ovarian Mucinous CystadenocarcinomaIndication
Ovarian Serous CystadenocarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Uterine Corpus CancerIndication
Solid TumorIndication
Stage IIIA Fallopian Tube Cancer AJCC v7Indication
Ovarian Cancer AJCC Stage IIIA v6 and v7Indication
Primary Peritoneal CancerIndication
Fallopian Tube CancerIndication
Ovarian CancerIndication
Peritoneal CancerIndication
Bladder Urothelial CarcinomaIndication
Transitional Cell CarcinomaIndication
Metastatic Urothelial CarcinomaIndication
Bladder CarcinomaIndication
Bladder Urothelial Carcinoma AJCC v7Indication
Pancreatic Neuroendocrine Tumor Grade 2Indication
Pancreatic Neuroendocrine CarcinomaIndication
Malignant NeoplasmIndication
Fibrolamellar CarcinomaIndication
Metastatic Malignant Solid NeoplasmIndication
Pancreatic Neuroendocrine TumorIndication
Recurrent Malignant Solid NeoplasmIndication
Malignant Solid NeoplasmIndication
NeoplasmIndication
Acute Lymphoblastic LeukemiaIndication
Philadelphia Chromosome NegativeIndication
Adult Acute Lymphoblastic LeukemiaIndication
LymphomaIndication
Multiple MyelomaIndication
Refractory NeoplasmIndication
GliosarcomaIndication
Leptomeningeal NeoplasmIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Brain MetastasesIndication
Recurrent Lung Non-Small Cell CarcinomaIndication
Stage IV Lung CancerIndication
Lung Cancer Stage IVA AJCC v8Indication
Lung CancerIndication
Stage III Lung Non-Small Cell CancerIndication
Stage IIIA Lung Non-Small Cell CancerIndication
Stage IIIB Lung CancerIndication
Endometrial CancerClinical trial
A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or FulvestrantStatus: Completed, Estimated PCD: 2018-06-29
Clinical trial
A Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2016-06-10
Clinical trial
An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor TherapyStatus: Completed, Estimated PCD: 2019-11-25
Clinical trial
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2020-12-31
Clinical trial
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 MutationStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)Status: Completed, Estimated PCD: 2021-05-11
Clinical trial
Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced CancersStatus: Completed, Estimated PCD: 2021-06-29
Clinical trial
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)Status: Active (not recruiting), Estimated PCD: 2018-12-28
Clinical trial
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients With Tumors Wtih mTOR MutationsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced CancersStatus: Completed, Estimated PCD: 2022-12-21
Clinical trial
Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) PatientsStatus: Terminated, Estimated PCD: 2020-01-31
Clinical trial
A Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Advanced NSCLC PatientsStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients With Tumors With TSC1 or TSC2 MutationsStatus: Active (not recruiting), Estimated PCD: 2025-01-06
Clinical trial
A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase InhibitorStatus: Active (not recruiting), Estimated PCD: 2024-06-29
Clinical trial
A Ph1b Study of Osimertinib + Alisertib or Sapanisertib for Osimertinib-Resistant EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) (Crossover Study)Status: Completed, Estimated PCD: 2023-07-27
Clinical trial
A Randomized, Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced or Recurrent Endometrial CancerStatus: Not yet recruiting, Estimated PCD: 2028-09-01